Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SLDBCHARLESTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 7,000 restricted stock units (“RSUs”) to one newly hired employee.
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
SLDBCHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening Panel (RUSP), the list of conditions recommended for universal newborn screening across the United States.
Solid Biosciences to Participate at Upcoming Investor Conferences
SLDBCHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
JMP Securities Reiterates Market Outperform on Solid Biosciences, Maintains $15 Price Target
SLDBCantor Fitzgerald Assumes Solid Biosciences at Overweight, Announces Price Target of $16
SLDBChardan Capital Maintains Buy on Solid Biosciences, Lowers Price Target to $15
SLDBPiper Sandler Maintains Overweight on Solid Biosciences, Lowers Price Target to $17
SLDBWedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $17
SLDBBarclays Maintains Overweight on Solid Biosciences, Lowers Price Target to $10
SLDBSolid Biosciences Q1 EPS $(0.59) Misses $(0.56) Estimate
SLDBJP Morgan Maintains Overweight on Solid Biosciences, Lowers Price Target to $11
SLDBHC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $20
SLDBChardan Capital Maintains Buy on Solid Biosciences, Maintains $16 Price Target
SLDBCitizens Capital Markets Reiterates Market Outperform on Solid Biosciences, Maintains $15 Price Target
SLDBSolid Biosciences Q4 2024 GAAP EPS $(1.00) Misses $(0.81) Estimate
SLDBChardan Capital Maintains Buy on Solid Biosciences, Raises Price Target to $16
SLDBSolid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
SLDBSolid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Solid Biosciences Reports Early Gene Therapy Results for Duchenne Muscular Dystrophy
SLDBSolid Biosciences Announces Clinical Pipeline Updates: SGT-003 Tolerated In Duchenne Trial; SGT-212 FA Study For 2H 2025; SGT-501 IND Submission By H1 2025; $148.9M Cash Funding Through 2026
SLDBHC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
SLDBHC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
SLDBSolid Biosciences Added To Nasdaq Biotechnology Index
SLDBSolid Biosciences Q3 EPS $(0.79) Misses $(0.67) Estimate
SLDBHC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
SLDBBarclays Maintains Overweight on Solid Biosciences, Lowers Price Target to $18
SLDBLooking Into Solid Biosciences's Return On Capital Employed
SLDBSolid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.
Piper Sandler Maintains Neutral on Solid Biosciences, Lowers Price Target to $5
SLDBSVB Leerink Maintains Outperform on Solid Biosciences, Raises Price Target to $15
SLDBChardan Capital Maintains Buy on Solid Biosciences, Lowers Price Target to $7
SLDB